Ebola Outbreak in DR Congo Spurs Vaccine Race
Quick Look
- A rare Ebola strain outbreak in DR Congo is escalating, prompting a race for vaccines and treatments.
- The Bundibugyo strain, unlike the Zaire strain, has no approved vaccines or treatments, though candidates exist.
- WHO is evaluating options, including Ervebo, which targets the Zaire strain.
AI-generated summary
Why It Matters
An escalating outbreak of a rare Ebola strain, the Bundibugyo strain, has occurred in the Democratic Republic of Congo. This is the 17th Ebola outbreak in the country, but only the third caused by this specific strain, for which no approved vaccines or treatments exist.
An escalating outbreak of a rare Ebola strain in the Democratic Republic of Congo has kicked off a race to find vaccines and treatments that can be quickly tested and rolled out to save lives and stem the crisis.
Tedros pointed to the emergence of cases in urban areas, the deaths of healthcare workers, and significant population movement as drivers of the spread.
It is the 17th Ebola outbreak in DR Congo, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
However scientists have developed numerous candidates for vaccines and treatments that have not yet been tested in humans.
The WHO has said it would examine the options, including a vaccine called Ervebo that targets the more common Zaire strain and has already been deployed in numerous countries.
Open Questions
- What is the current number of cases and deaths?
- How quickly can potential vaccines and treatments be developed and tested?
- What is the extent of population movement and its impact on spread?
- Will Ervebo be effective against the Bundibugyo strain, or will new candidates be prioritized?
